J. Safra Sarasin Holding AG Has $117.67 Million Stock Position in Johnson & Johnson $JNJ

J. Safra Sarasin Holding AG grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 481,585 shares of the company’s stock after purchasing an additional 2,782 shares during the quarter. Johnson & Johnson makes up approximately 2.0% of J. Safra Sarasin Holding AG’s investment portfolio, making the stock its 6th largest position. J. Safra Sarasin Holding AG’s holdings in Johnson & Johnson were worth $117,669,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Hibernia Wealth Partners LLC increased its stake in Johnson & Johnson by 25.4% in the 1st quarter. Hibernia Wealth Partners LLC now owns 1,683 shares of the company’s stock worth $411,000 after buying an additional 341 shares during the period. Lifeworks Advisors LLC boosted its position in Johnson & Johnson by 1.4% in the 1st quarter. Lifeworks Advisors LLC now owns 36,895 shares of the company’s stock valued at $9,019,000 after buying an additional 520 shares during the period. Avion Wealth grew its stake in Johnson & Johnson by 68.5% in the 1st quarter. Avion Wealth now owns 1,586 shares of the company’s stock worth $387,000 after acquiring an additional 645 shares in the last quarter. LGT Fund Management Co Ltd. grew its stake in Johnson & Johnson by 770.7% in the 1st quarter. LGT Fund Management Co Ltd. now owns 112,310 shares of the company’s stock worth $27,453,000 after acquiring an additional 99,411 shares in the last quarter. Finally, Castleview Partners LLC increased its position in shares of Johnson & Johnson by 7.5% during the first quarter. Castleview Partners LLC now owns 2,914 shares of the company’s stock worth $712,000 after acquiring an additional 203 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JNJ. Daiwa Securities Group boosted their price target on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. Morgan Stanley raised their price objective on Johnson & Johnson from $283.00 to $284.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, July 6th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. Finally, Guggenheim raised their price target on Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, June 26th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $261.26.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 1.6%

JNJ opened at $253.70 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The firm has a market cap of $610.71 billion, a price-to-earnings ratio of 29.33, a PEG ratio of 2.46 and a beta of 0.24. Johnson & Johnson has a 12 month low of $154.80 and a 12 month high of $269.43. The stock has a fifty day moving average price of $238.18 and a 200-day moving average price of $233.92.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.77 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts expect Johnson & Johnson to post a solid Q2 print, with commentary pointing to an upbeat report even as Stelara faces headwinds. Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds
• Positive Sentiment: Several preview pieces say JNJ is trading near all-time highs and could still have more upside if earnings and guidance come in strong. Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282
• Positive Sentiment: RBC raised its price target on JNJ to $287 from $265 and maintained an outperform rating, reinforcing bullish sentiment.
• Positive Sentiment: Coverage also highlighted JNJ’s strong year-to-date run and defensive healthcare appeal, which has supported investor demand ahead of earnings. Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.
• Neutral Sentiment: Other articles focused on JNJ as a dividend and income stock, which may support valuation but did not add new material catalysts. How to earn $500 a month from Johnson & Johnson stock ahead of Q2 earnings
• Negative Sentiment: Some commentary noted the stock’s rich valuation after a big rally, suggesting investors may be paying a premium heading into the report. What Lilly’s Peer-Beating Numbers Cost You

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.